

BELLEVUE ASSET MANAGEMENT

PRESS RELEASE

Küsnacht, June 14, 2010

Investment expertise in healthcare sector strengthened

Bellevue Asset Management creates independent Advisory Board

As part of the systematic expansion of its sector and investing expertise, Bellevue Asset Management has created a Healthcare Advisory Board composed of highly qualified executives with many years of experience as well as distinguished scientists. This further strengthens the company's proven competency in the healthcare sector as well as its already extensive international network. The objectives here are detecting mega trends and investment opportunities at a very early stage, systematically identifying groundbreaking innovations and realistically evaluating their prospects of success and, ultimately, using this knowledge to make sound and successful investment decisions.

The creation of an independent Healthcare Advisory Board marks another step forward in the steadfast implementation of Bellevue Asset Management's strategic expansion of its asset management business. The company has attracted prominent executives and experts with excellent credentials and track records to its international Advisory Board. They are industry representatives with high R&D competence and who are very familiar with regulatory processes or have decades of experience in managing international companies. The newly constituted board chaired by William M. Burns, former CEO of the Pharma Division at Roche, will focus its attention on trends and investment opportunities in the healthcare sector.

The board members, internationally recognized experts representing diverse industrial and academic backgrounds, will advise the investment specialists at Bellevue Asset Management and support them in the evaluation of consequential medical and technical innovations in the biotechnology and medical technology sectors as well as in other areas, including the corresponding investment possibilities.

"The innovative forces at work in the healthcare sector remain as strong as ever, which makes the early detection of critical trends and an accurate assessment of the chances of their successful commercial realization all the more important. We are looking forward to a fruitful and rewarding interdisciplinary exchange of knowledge and ideas with the portfolio managers," says William M. Burns, Chairman of the Advisory Board. Hans-Peter Diener, CEO of Bellevue Asset Management, adds: "We are honored to be able to consult such high-caliber professionals while screening, evaluating and realizing investment opportunities, for it is only through an active discourse with the best experts worldwide that specialist knowledge and expertise can be maintained and developed at internationally competitive levels. This, in turn, enables us to detect future investment ideas early on and realistically assess their prospects."

The Healthcare Advisory Board consists of the following experts:

William M. Burns (Chairman)

Board member of Roche Group; ex-CEO Roche Pharma; Board member of Chugai and member of the Advisory Board of Genentech; Board member of Shire and Crucell

Prof. Dr. Dr. Uwe Bicker

Aventis Foundation trustee; Board member of Sanofi-Aventis; Vice Chairman of Epigenomics AG; Professor at

the Faculty of Clinical Medicine Mannheim, University of Heidelberg

Prof. Dr. Stefan Catsicas

Co-founder of the Tilocor Life Science biotechnology group; Former Professor at the School of Medicine in Lausanne and Professor, Vice President and Research Director at the Swiss Federal Institute of Technology (Lausanne)

Dr. Jürgen Schwiezer

Ex-CEO Roche Diagnostics

Prof. Dr. Thomas Szucs

Chairman of Helsana Group and BB Biotech AG; Director of the Institute of Pharmaceutical Medicine at the University of Basel

Prof. Dr. Otmar D. Wiestler

Chairman of the Management Board and Scientific Director of the German Cancer Research Center, Heidelberg

Bellevue Asset Management is one of the leading providers of investment management services in the healthcare sector, specifically in medical technology and biotechnology. 14 experts in the fields of biochemistry, molecular biology, medicine and economics manage approximately CHF 2.2 billion using specialized sector strategies in the healthcare sector. With an average of 10 years of professional experience and a network of contacts spanning the globe, they are a key factor for competitive and sustainable investment success.

Based on its profound healthcare expertise Bellevue Asset Management offers a comprehensive range of investment vehicles:

Traditional investment vehicles

BB Biotech AG (listed investment company)
BB Biotech (Lux) Fund
BB Medtech (Lux) Fund
BB Healthcare (Lux) Fund

Non-traditional investment vehicles

BB Bioventures
BB Biotech Ventures II - III
BB Alpha Health (long/short equity fund)

For further information:

Bellevue Asset Management AG, Seestrasse 16/P.O. Box, CH-8700 Küsnacht/Zurich

Thomas Egger, Tel. +41 (44) 267 67 09, teg@bellevue.ch

Images available [here](#)

(http://www.bellevue.ch/cms/bellevue_asset_management/page3508.html)

Bellevue Asset Management

Bellevue Asset Management is an independent and highly specialized asset management boutique focused on managing equity portfolios for selective sector and regional strategies as well as institutional portfolios, particularly in the areas of healthcare, new markets and Swiss/European equities.